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Peripheral blood lymphocyte cell subsets in subjects 
with chronic obstructive pulmonary disease: 
association with smoking, IgE and lung function 
J. W. DE JONG, B. VAN DER BELT-GRITTER, G. H. KO~~TER AND D. S. POSTMA 
Department of Pulmono~ogy, University Hospital Guoningen, The Nethedands 
In contrast to the numerous studies which show that lymphocytes play an important role in the 
pathogenesis of asthma, few studies have investigated the role of lymphocytes in the pathogenesis of 
chronic obstructive pul.monary disease (COPD). The aim of the present study was to investigate 
lymphocyte subsets in peripheral venous blood of smoking and non-smoking COPD patients and 
healthy controls. The interaction of smoking and IgE has also been assessed, and it was investigated 
whether a lower level of FEV, was associated with changes in lymphocyte subsets. 
In the present study, peripheral venous blood lymphocyte subsets were investigated in 42 smoking and 
non-smoking, non-atopic subjects with a clear diagnosis of COPD (43-74 years) who all used 
bronchodilator therapy only, and in 24 normal, healthy control subjects (40-72 years). 
No significant differences in lymphocyte subsets were found when either total groups or smoking 
subjects of both groups were compared. However, the percentage of CD8+ lymphocytes (suppressor/ 
cytotoxic T-cells) was significantly higher in the non-smoking COPD subjects compared with the 
non-smoking, healthy control subjects (PcO.05). In addition, within the group of non-smoking COPD 
subjects, a higher CD4:CDS ratio was associated with a higher FEV, as a percentage of predicted (% 
pred.) (r=0.55, P=O.Ol) and a lower total serum IgE (u= - 0.45, P=O.O4). Within the group of smoking 
COPD subjects, a higher FEV, % pred. was associated with a higher percentage of CD19’ lymphocytes 
(B-cells) (v=O.65, P<O.Ol). 
The present study provides further evidence that the changes in the balance of T-cell subsets and IgE 
synthesis possibly plays a role in the pathogenesis of COPD. 
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Introduction 
Cigarette smoking is the most important risk 
factor for development and progression of 
chronic obstructive pulmonary disease (COPD) 
(1). However, only 15-20X of cigarette smokers 
develop clinically significant airways obstruction 
(2). Several mechanisms for an increased suscep- 
tibility in this subgroup of smokers have been 
suggested. Attention has been focused on the 
role of polymorphonuclear leukocytes (PMN) in 
the pathophysiology of COPD, as their numbers 
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have been found to be increased in the broncho- 
alveolar lavage of smoking COPD patients 
(3-5). Cigarette smoke may directly recruit 
leukocytes to the Eu~, and indirectly via 
cytokine release from activated macrophages 
(6,7). Also, adhesion molecules, neuroendocrine 
cells and neuropeptides have been suggested 
as other possibly important factors in the 
pathogenesis of COPD (X,9). 
Lymphocytes are known to modulate inflam- 
matory processes in the airways of asthmatics 
(10-12). However, little has been published 
about their role in the pathogenesis of COPD 
(13-15). Moreover, smoking and non-smoking 
patients with different characteristics had been 
included in these studies (13-l 5), preventing firm 
conclusions. Studies in healthy subjects have 
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demonstrated a considerable influence of ciga- 
rette smoking, age and gender on lymphocyte 
subsets (16-20). Since a distinct characterization 
of the patients in the latter studies has not been 
performed, it is not clear whether patients with 
COPD were included. 
To investigate a role of lymphocytes and their 
activation in the pathogenesis of COPD, a study 
was designed to compare lymphocyte subsets in 
peripheral venous blood of smoking and non- 
smoking COPD patients with healthy controls. 
As smokers do have higher serum immuno- 
globulin E (IgE) levels, and high IgE levels have 
been associated with the development of COPD 
(21), the interaction of smoking and IgE have 
also been assessed. Finally, it was investigated 
whether a lower level of FEV, was associated 
with changes in lymphocyte subsets. 
Methods 
SUBJECTS 
All COPD patients selected for this study met 
the following inclusion criteria: (1) aged 40 years 
or older, current, former or never-smokers 
without a history of asthmatic attacks, reporting 
either chronic cough with or without sputum 
production or dyspnoea when walking quietly 
on level ground, or both (22), and without other 
major diseases; (2) no atopy, defined by negative 
skin tests (Diephuis Laboratories, Groningen, 
The Netherlands), no detectable specific serum 
IgE to house dust mite (HDM), and total serum 
IgE levels ~350 IU ml - ‘; (3) forced expiratory 
volume in 1 s (FEV,) more than 11 and less than 
70% of predicted (% pred.), without medication 
for the previous 8 h; FEV, after 40 mg ipratro- 
pium bromide less than 80% pred.; (4) the con- 
centration of methacholine causing a 20% 
decrease of FEV, from baseline (PC,,) less than 
8mgml-‘; (5) no upper respiratory tract infec- 
tion or exacerbation within 6 weeks before the 
start of the study. 
Control subjects were normal, smoking or 
non-smoking, healthy volunteers of either sex, 
aged 40 years or older taking no medication, 
without a history of atopy or bronchial obstruc- 
tion and therefore not satisfying the ATS criteria 
for asthma or COPD (22) with no detectable 
specific IgE to HDM, and total serum IgE within 
the normal range. The FEV, had to be greater 
than 80% pred. 
Chronic obstructive pulmonary disease 
patients visited the hospital on two separate 
days. On the first day, lung function and PC,, 
methacholine were assessed. Theophylline was 
discontinued for 48 h, and other bronchodilators 
were discontinued for 8 h before each visit to 
the hospital. The use of inhaled corticosteroids 
was stopped 4 weeks before the start of the 
study; oral corticosteroids, cromolyn sodium, 
nedocromil sodium or anti-histamines were not 
used. Within 2 weeks, on the second day, periph- 
eral venous blood was drawn to investigate the 
lymphocyte subsets. The control subjects visited 
the hospital on 1 day. After an extensive history 
had been taken to exclude any pulmonary symp- 
toms, lung function was carried out, and blood 
was withdrawn for determination of specific and 
total serum IgE and lymphocyte subsets. Sub- 
jects, either COPD patients or healthy controls, 
who smoked cigarettes at the time of the study 
were considered to be ‘current’ smokers; all 
others were considered to be non-smokers 
(smoking cessation > 1 yr or never-smokers). The 
study was approved by the Hospital Medical 
Ethics Committee and all subjects gave their 
written informed consent to participate. 
BRONCHIAL PROVOCATION 
Spirometry was performed using a calibrated 
water-sealed spirometer (Lode BV, Groningen, 
The Netherlands) according to standardized 
guidelines. Baseline FEV, and forced vital 
capacity (FVC) were measured until three repro- 
ducible recordings were obtained. Highest values 
were used for analysis. Reference values are 
those of the European Community for Coal and 
Steel (23). FEV, was expressed as a percentage 
of predicted FEV, (FEV, % pred.). 
A solution of methacholine bromide was 
administered as an aerosol generated from a 
starting volume of 3 ml in a DeVilbiss 646 
nebulizer (De Vilbiss Co., Somerset, PA, 
U.S.A.), connected to the central chamber of an 
inspiratory-expiratory valve box. Solution out- 
putwas0*13mlmin-‘. After inhalation of 0.9% 
sodium chloride, subjects inhaled doubling con- 
centrations of methacholine bromide for 2 min, 
ranging from 0.0367 to 256 mg ml- ‘, at 5-min 
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intervals. FEV, was measured 30 and 90 s 
after each inhalation until it was less than 80% 
of the pre-challenge value. PC,, values were 
determined by linear interpolation between 
the last two data points on the logarithmic 
concentration-response curve. 
SAMPLING OF PERIPHERAL BLOOD 
MONONUCLEAR CELLS 
Peripheral venous blood samples (30 ml) were 
anticoagulated with EDTA. Blood mononuclear 
cells were separated using ‘Ficoll-Paque’ den- 
sity gradient centrifugation (Pharmacia Fine 
Chemicals). Mononuclear cells were resuspended 
in ammonium chloride for 5 min at 4°C and 
centrifugated at 970 g for 5 min at the same 
temperature. Subsequently, the mononuclear 
cells were washed twice in phosphate-buffered 
saline (PBS) and 0.1% glucose, and centrifugated 
at 970 g for 5 min, and subsequently at 170 g for 
10 min, both at 4°C. The mononuclear cell con- 
centration was determined by using a Coulter 
Counter, and viability, as tested by Trypan blue 
exclusion, was always higher than 95%. Suspen- 
sions of 100 ml cells (0.4 X lo6 cells ml - ’ in 
PBS) were taken for further lymphocyte-subset 
determination by flow cytometry. 
MONONUCLEAR CELL STAINING AND 
FLOW CYTOMETRY 
Isolated mononuclear cells were prepared for 
two-colour immunofluorescence analysis with 
monoclonal antibodies anti-CD3 (Leu-4), anti- 
CD4 (Leu-3a), anti-CD8 (Leu-2a), anti-CD19 
(Leu-12), CD45RO (UCHLl), anti-CD56 
(Leu-19) and anti-CD16 (Leu-llc) (Becton- 
Dickinson, Mountain View, CA, U.S.A.) conju- 
gated to phycoerythrin (PE) or fluorescein 
isothiocyanate (FITC) to identify T-cells, 
T-helper/inducer cells (CD4’), T-cytotoxic/ 
suppressor cells (CD8’), B-cells (CD19+), acti- 
vated or memory T-cells (UCHLl ‘) and natural 
killer (NK) cells, respectively. The final cell 
concentration in each sample was adjusted to 
1 X lo6 cells ml - i in PBS and 0.5% bovine 
serum albumin (BSA). The cells were centri- 
fugated at 530 g for 5 min at 10°C and sub- 
sequently incubated for 30 min at 4°C with 
appropriate dilutions of monoclonal antibodies. 
Unspecific binding was checked using FITC and 
PE-labelled control antibodies. After the cells 
had been washed twice with PBS and 0.5% BSA, 
they were centrifugated at 530 g for 5 min at 4°C. 
After the addition of PBS with 0.5% BSA, the 
incubated cells were stored in the dark at 4°C 
until analysis. 
Flow cytometry was performed on a Becton- 
Dickinson FACS Analyser, equipped with an 
argon laser and interfaced with a Hewlett- 
Packard Consort 30 computer. For each (com- 
bination of) monoclonal antibody (antibodies), 
PO 000 mononuclear cells were counted and 
gated with forward and sideward scatter to 
detect lymphocytes from other leukocytes. Sub- 
sequently, the lymphocyte gate was set on the 
image of the combined monocyte marker CD14 
(Leu-m3) and the total leukocyte marker CD45 
(Hle-1) scatter in order to exclude contamination 
from erythrocytes and debris, and to exclude 
monocytes and granulocytes. 
MEASUREMENT OF TOTAL SERUM IgE 
Total serum IgE (expressed in IU ml - ‘) was 
measured using an enzymatic in vitro test sys- 
tem (Phadezym RASTa) based on the Radio 
Allergo Sorbent Test principle for determi- 
nation of circulating IgE antibodies in human 
serum in a sample of blood (normal values 
< 120 IU ml - i, but smokers may have higher 
values). 
STATISTICAL ANALYSIS 
Skewness of distributions was assessed with 
Kolmogorov-Smirnov tests. To get a normal 
distribution, IgE was logarithmically trans- 
formed, which was also necessary for the pro- 
portion of CD19 positive lymphocytes by using 
a logistic transformation for proportions (J): 
y = ln[p/( 1 -p)]. Lymphocyte cell subsets are 
expressed as a percentage of lymphocytes, 
whereas UCHLl+ CD3 or UCHLI + CD4 cells 
are expressed in percentages of the proportion of 
CD3+ or CD4+ T-cells which is UCHLl posi- 
tive. PC,, values were analysed after base 2 
logarithmic transformation, one log unit being 
one dose step in concentration. 
Differences between (sub)groups of patients 
with COPD and healthy control subjects were 
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FIG. 1. *Non-smoking chronic obstructive pul- 
monary disease (COPD) patients with a significantly 
higher percentage of CD8+ lymphocytes than 
non-smoking healthy controls (PcO.05). Horizontal 
lines represent median values, bars represent the 
interquartile ranges and vertical lines represent the 
full range of values. CSM, current smokers; 
NSM. non-smokers. 
determined by analysis of co-variance taking 
age, gender and pack-years as co-variables. Mul- 
tiple linear regression analysis with stepwise 
method was used to identify variables or groups 
of variables that were most strongly associated 
with the dependent variable FEV, % pred. Two- 
tailed tests have been used throughout at the 
95% level of significance. All analysis were per- 
formed with the SPSS/PC+ package (24). All the 
data are expressed in mean f SD, except for the 
data presentation in Fig. 1 for which medians 
and interquartile ranges were also used. 
Results 
PATIENTS 
Forty-two COPD patients and 24 normal, 
healthy, control Caucasian subjects satisfied the 
inclusion criteria. Healthy control subjects dif- 
fered significantly in that they were younger, had 
a smaller number of pack-years and better lung 
function (selection criterion). This was also the 
case when the smoking, healthy control subjects 
were compared with the smoking COPD 
patients, whereas the non-smoking, healthy con- 
trols only had a significantly better lung function 
(Table 1). 
Within the COPD group, current smokers had 
a significantly higher total serum IgE than non- 
smokers. Within the group of non-smoking 
COPD patients, total serum IgE turned out to 
be negatively associated with FEV, % pred. 
(r= - 0.44, P= 0.04). This association was not 
found within the other three subgroups. Within 
the group of healthy controls, the current 
smokers were significantly younger and had 
higher total serum IgE than the non-smokers. 
LYMPHOCYTE MARKERS 
Diffeevences Between COPD and Healthy Control 
(5ub)Groups (Fig. 1 and Table 2) 
Mean percentages of lymphocyte cell subsets of 
the COPD and healthy control groups were not 
significantly different. No significant differences 
were found between smoking COPD patients 
and smoking healthy controls. Non-smoking 
COPD patients had a significantly higher per- 
centage of CD8+ lymphocytes than non- 
smoking healthy controls (38.2 f 11.7 and 
30.2 f 7.8, respectively, PcO.05). No significant 
differences in activation of CD3+ or CD4+ 
lymphocytes between the COPD patients and 
healthy controls, or between the four subgroups 
was found. 
Relationship with Smoking (Table 2) 
Within the healthy control group, smokers had a 
significantly lower percentage of CD16+/CD56+ 
lymphocytes than non-smokers (12.7 f 4.1 and 
16.7 f 4.2, respectively, P<O*OS). The percentage 
of CD19+ lymphocytes was not significantly 
different (12.1 f 4.4 and 9.2 f 4.2, respectively). 
Otherwise, lymphocyte cell subsets were compar- 
able. Within the COPD group, smokers had a 
significantly higher percentage of CD19’ lym- 
phocytes than non-smokers (12.3 f 5.6 and 
7.5 Ilt 3.3, respectively, P<OeOl). The percentage 
of CD16+/CD56’ lymphocytes was not sig- 
nificantly different (13.4 f 7.5 and 17.8 f 7.6, 
respectively). 
Relationship with FEV, % pred. (Figs 2 and 3) 
When pooling patients with COPD and healthy 
controls in a multiple linear regression model, 
TABLE 1. Subject characteristics 
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Subjects with COPD 
Current smokers Non-smokers 
(n=21) (n=21) 
Age (years) 
Gender (F/M) 
FEV, (% pred.) 
FEV,/FVC (%) 
Reversibility (AFEV, % pred.) 
PC,, methacholine (mg ml - ‘)* 
Total IgE (IU ml - ‘)* 
AtOm 
Current/former/never-smoking 
Cigarettes (day - ‘) 
Pack-years 
58.8 ir 8.0 
l/20 
49.1 + 12.5 
45.1 * 10 5 
8.4 f 5.0 
0.3 
60.97 
Negative 
21/o/o 
14.1 f 9.9 
242 f 8.8 
62.1 ?c 6.9 
2119 
49.4 zt 11.6 
46.5 rt 11.6 
5.4 f 3.3 
0.5 
35.2 
Negative 
O/16/5 
0 
18.8 i 15.3 
Healthy control subjects 
Current smokers 
(n=9) 
Non-smokers 
(n=15) 
Age (years) 
Gender (F/M) 
FEV, (% pred.) 
FEV,/FVC (%) 
Total IgE (IU ml - ‘)* 
AtOm 
Current/former/never-smoking 
Cigarettes (day - i) 
Pack-years 
46.1 f 5.3$!1 
l/8 
103.9 zt 1oq 
76.5 i: 5.311 
53.5 
Negative 
9/o/o 
11.8 f 7.1 
13.4 & 9.71’ 
57.5 zt 8.8 
2113 
106.6 xt 10.65 
76.0 + 6.65 
32.1 
Negative 
o/14/1 
0 
13.0 + Il.0 
COPD, chronic obstructive pulmonary disease. 
“Geometric mean. 
f-P significantly different in smoking compared with non-smoking COPD subjects 
(PCO.05). 
$P significantly different in smoking compared with non-smoking, healthy control subjects 
(P<O.Ol). 
$P significantly different in non-smoking, healthy controls compared with non-smoking 
COPD subjects (BO.01). 
IlP significantly different in smoking, healthy controls compared with smoking COPD 
subjects (BO.01). 
FEV, % pred. was negatively associated with 
smoking (B= - 15.2, P-0*03), age (B= - 1.2, 
P= 0.004), pack-years (B= - 0.5, P= 0.06) and 
CD8+ lymphocytes (B= - 0.7, P=O.O4) 
(u2=0.32), gg t’ su es mg that non-smoking patients 
with low FEV, (COPD) have a higher percent- 
age of CD8+ lymphocytes. Within the group of 
non-smoking COPD patients, FEV, % pred. was 
significantly associated with the percentage of 
CD4+ lymphocytes (r=0.58, P=O.O07) and the 
CD4:CD8 ratio (v=O.55, P=O.Ol) (Fig. 2), also 
without the outlier (CD4:CD8 ratio 3.1). These 
associations were not significant in the group 
of smoking COPD patients, and the groups of 
non-smoking and smoking, healthy control 
subjects. 
Within the group of smoking COPD patients, 
FEV, % pred. was significantly associated with 
the percentage of CD19+ lymphocytes (~~0.65, 
P<O.Ol) (Fig. 3). No significant association 
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TABLE 2. Lymphocyte subsets in subjects with chronic obstructive pulmonary disease 
(COPD) and healthy controls, subdivided into smokers and non-smokers 
Cell surface 
antigen 
COPD COPD Healthy control Healthy control 
smokers non-smokers smokers non-smokers 
CD3 69.0 zt 10.9 70.3 f 10.3 71.4 5 8.1 70.0 I.L 8.1 
CD4 41.1 It 10,4 36.9 f 10.4 44.0 f 5.2 43.1 It 8.1 
CDS 31.2 & 9.6 38.2 f 11.7s 29.9 f 6.4 30.2 * 7.8 
CD4:CD8 ratio 1.5ztO.6 ’ 1.1 * 0.6 1.5 + 0.4 1.6 + 0.6 
CD19 12.3 f 5.6 7.5 It 3.33 12.1 zt 4.4 9.2 dr 4.2 
CD16/CD56 13.4 f 7.5 17.8 * 7.6 12.7 Z!I 4.1 16.7 f 4.2t 
UCHLl CD3* 62.2 f 13.8 56.3 f 12.6 59.4 f 13.1 58.7 f 12.0 
UCHLl CD4” 65.2 zt 17.3 59.3 + 15.7 61.9 & 15.2 58.3 f 16.3 
Values are expressed as a percentage of lymphocytes. 
*Percentage of the proportion CD3’ or CD4+ T-cells which is UCHLl positive. 
tBO.05 comparing healthy control non-smokers with healthy control smokers. 
$P<O.Ol comparing COPD non-smokers with COPD smokers. 
gBO.05 comparing COPD non-smokers with healthy control non-smokers. 
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FIG. 2. Relationship between FEV, % predicted 
and the CD4:CD8 ratio within the group of non- 
smoking chronic obstructive pulmonary disease 
patients (r=0.55, P=O.Ol). 
between FEV, % pred. and CD19+ lymphocytes 
was found within other (sub)groups. 
Relationship with Serum IgE [Fig. 4) 
Within the group of non-smoking COPD sub- 
jects, total serum IgE was negatively associated 
30 r 
25 
20 30 40 50 60 70 80 
FEV, (% predicted) 
FIG. 3. Relationship between FEV, % predicted 
and CD19’ lymphocytes within the group of smok- 
ing chronic obstructive pulmonary disease patients 
(r = 0.65, BO.01). 
with the percentage of CD4+ lymphocytes 
(r= - 0.48, P= 0.03) and with the CD4:CD8 
ratio (r= - O-45, P=O+OO4) (Fig. 4).The associ- 
ation between the percentage of CD8’ lym- 
phocytes and total serum IgE was more 
pronounced within the group of smoking COPD 
0 I 
I I I I I / 
2 3 4 5 6 
Total serum IgE (log,) 
i 
7 
FIG. 4. Relationship between total serum immuno- 
globulin E and CD4:CD8 ratio within the group of 
non-smoking chronic obstructive puhnonary disease 
patients (r= - 0.45, P=O.O4). 
subjects (r= 0.50, P=O.O2). No other significant 
association between total serum IgE and 
lymphocyte subsets was found within other 
(sub)- groups. 
Discussion 
This study has investigated peripheral venous 
blood lymphocyte subsels of non-atopic in- 
dividuals with COPD and healthy controls in 
order to find evidence that lymphocytes may be 
implicated in the disease entity, COPD. Mean 
percentages of lymphocyte cell subsets of the 
COPD and healthy control groups as a whole 
were not significantly diRerent. No significant 
differences in lymphocyte subsets were observed 
between smoking COPD patients and smoking 
healthy controls. This may be due to the fact 
that current smoking itself affects the proportion 
of lymphocyte cell subsets (16-20), and that 
non-smoking patients with COPD may be more 
severely affected by their disease as has been 
suggested by Fletcher et al. (2). By comparing 
non-smoking groups, a clearer interpretation 
of differences in lymphocyte cell subsets in 
smoking-affected and non-affected individuals is 
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possible. The present results show that the per- 
centage of CD8’ lymphocytes was significantly 
higher in the non-smoking COPD subjects 
(Fig. 1). 
In contrast to the present findings in COPD, 
Walker et al. (11) found peripheral blood CD8+ 
lymphocytes of non-smoking, non-atopic asth- 
matics to be decreased in blood, and increased in 
bronchoalveolar lavage fluid (BAL). In asth- 
matic patients who all developed early-phase 
responses after inhalation of allergen, Gonzalez 
et al. (12) found a discrepancy between lym- 
phocyte subsets measured in peripheral blood 
and bronchoalveolar lavage, suggesting that 
mobilization of suppressor T-cells into the lung 
occurred after inhalation of allergen. Therefore, 
in the present study, it is not clear whether it may 
be assumed that peripheral blood lymphocyte 
cell subsets reflect ongoing processes in the lung. 
It is also conceivable that the higher percentages 
of peripheral venous blood lymphocyte subsets 
of non-smokers in the present study are in fact 
reflecting lower percentages of lymphocyte sub- 
sets in the lung. This would be in contrast to the 
findings of Fournier et al. (13) who found a 
significant increase in CD8+ lymphocytes in the 
airway wall in smoking patients with chronic 
bronchitis when compared with healthy control 
subjects. However, the patients’ characteristics 
of the study of Fournier et al. (13) are different 
from the non-smoking COPD patients of the 
present study in that they were heavy smokers 
with better lung function. 
An explanation for the role of CD8+ lym- 
phocyte subsets in patients with COPD may be 
their involvement in immunity to infectious 
agents (29, and COPD patients are known to be 
vulnerable to infections. An increase of blood 
CD8+ lymphocytes might thus reflect an over- 
shooted reaction in an attempt of the immuno- 
logical system to restitute normal immune 
functions. Blood CD8+ lymphocytes have also 
been found to be increased in healthy heavy 
smokers (18,20). The increased CD8+ lym- 
phocytes returned to lower values when sub- 
jects stopped smoking. In the present study, 
it is conceivable that the CD8’ lymphocytes 
of the non-smoking COPD subjects did not 
return to lower values after the moment they 
stopped smoking because they developed 
COPD. 
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Multiple regression analysis showed that non- 
smoking COPD patients with low FEV, have a 
significant higher percentage of CDS+ lym- 
phocytes. Moreover, within the group of non- 
smoking COPD patients, a low FEV, % pred. 
was significantly associated with both a lower 
percentage of CD4+ cells and a lower CD4:CD8 
ratio (Fig. 2). This may suggest that alterations 
in the balance of T-cell subsets are associated 
with the degree of airflow obstruction, especially 
in non-smoking patients with COPD. 
In the group of non-smoking COPD subjects, 
significant associations of total serum IgE were 
found with the percentage of CD4+ lymphocytes 
and the CD4:CDS ratio (Fig. 4). This may 
suggest that alterations in the balance of T-cell 
subsets are also implicated in IgE synthesis. This 
may be true within the group of smoking COPD 
patients, considering the significant association 
between total serum IgE and the percentage of 
CDS’ lymphocytes. 
Larramendy et al. (19) demonstrated that 
blood peripheral CD8+ and CD19+ lympho- 
cytes (B-cells) of smoking healthy subjects con- 
tained an increased frequency of micronuclei 
compared with non-smoking healthy subjects. 
This may be regarded as CD19’ and -CD8+ 
lymphocytes being more sensitive for changes to 
smoking, which may be important in the devel- 
opment of COPD. As shown in other studies 
(17,20,26-28) healthy and COPD smokers had a 
higher percentage of CD19+ lymphocytes and 
total serum IgE than healthy and COPD non- 
smokers. The effects of smoking may trigger the 
CD19+ lymphocytes to produce IgE. One may 
hypothesize that IgE and/or CD19+ lym- 
phocytes play a role in COPD. Several studies 
have shown that increased IgE levels in current 
smokers are negatively associated with FEY, % 
pred. (17,26-28). Although this IgE-FEV, re- 
lationship is thought to be a general phenom- 
enon in current smokers, the present study 
indicates that IgE may also be of importance in 
non-smoking COPD patients. In a recent paper, 
Villar et al. (21) have also suggested that IgE 
may be of significance in the pathogenesis of 
smoking-related airways obstruction. Bosken 
et al. (14) demonstrated that patients with air- 
ways obstruction had significantly more CD19+ 
lymphocytes in the airway wall than patients 
without airway obstruction. In the present study, 
the percentage of CD19+ lymphocytes was not 
different in the COPD (sub)groups compared 
with the healthy control (sub)groups. However, 
within the smoking COPD group, a lower FEV, 
% pred. was found in subjects with a lower 
percentage of CD19* lymphocytes (Fig. 3). In 
this respect, the present findings may support 
the hypothesis that CD19+ lymphocytes are 
mobilized into the lung, especially in COPD 
patients with a low FEV, % pred., resulting in 
a lower percentage of CD19+ lymphocytes in 
peripheral blood. 
In both smoking COPD and smoking, healthy 
control subjects, percentages of CD16+/CD56+ 
lymphocytes (NK cells) were decreased when 
compared with the non-smoking COPD and 
non-smoking, healthy control subjects. Tollerud 
et al. (29) also demonstrated that cigarette 
smoking is associated with a decrease in the 
proportion of circulating NK cells. As NK cells 
are considered to play an important role in anti- 
tumour immunity, a decrease of these cells may 
contribute to an increased risk of malignancies. 
Some general remarks on the present study 
have to be mentioned. Several studies, investigat- 
ing the role of airway inflammation in COPD, 
have studied patients with and without airway 
obstruction, and even allergic patients may have 
participated. In the present study, non-atopic 
patients with COPD were selected. All COPD 
patients had chronic airway obstruction, most of 
them with only little airway reversibility (AFEV, 
< 1’0% pred.). A small number of COPD patients 
(5) and one control patient had never smoked. 
The subject characteristics of the never-smoking 
patients with COPD were not significantly dif- 
ferent from the former smokers. Occupational 
diseases may have played a role in the develop- 
ment of COPD. However, only two male 
patients frequently came into contact with dust. 
It has also been suggested that neuropeptides 
may cause COPD, even in patients who have 
never smoked cigarettes (9). In a recent study, 
Lusuardi et al. (30) demonstrated the presence of 
airway inflammation in subjects with chronic 
bronchitis and airway obstruction (mean FEV, 
64% pred.) who had never smoked. In the 
present study, the healthy control subjects were 
not extensively matched with the COPD 
patients. This has been accounted for by means 
of co-variance analysis, adjusting for gender, age 
and the number of pack-years. Some findings in 
the present study, especially the influence of 
current smoking on IgE and lymphocyte subsets 
in patients with COPD and healthy controls, do 
correspond to the findings in epidemiological 
studies (16,27-29). This suggests the allowance 
of investigating lymphocyte subsets in relatively 
small groups of smoking and non-smoking 
patients. 
In summary, the present study described some 
peripheral blood immunological alterations 
which may play a role in the pathogenesis of 
COPD. It is evident that a complex interaction 
of smoking, changes in balances of T-cell subsets 
and IgE synthesis may be responsible for the 
development of COPD. However, the exact 
mechanisms for development of COPD have yet 
to be elucidated. Further studies especially inves- 
tigating airway tissues of smokers and non- 
smokers with COPD and healthy controls, by 
following smokers who stop smoking, are neces- 
sary to evaluate the results of the present study. 
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